Impact of Canagliflozin on Renoprotection in T2DM


Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
© 2024 MJH Life Sciences

All rights reserved.